NCT00217425 2023-06-18
Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms
Eastern Cooperative Oncology Group
Phase 2 Completed
Clinical Trials
15 trialsNCT01327612 2021-02-21
Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)
Amgen
Phase 2 Completed
NCT00722865 2017-10-18
Avastin (Bevacizumab) Plus Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) for Advanced Stage Hodgkin Lymphoma
Massachusetts General Hospital
Phase 2 Terminated
NCT00816595 2017-06-15
Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Mayo Clinic
Phase 2 Completed
NCT00788606 2016-10-14
R-CHOP-B Bevacizumab for Diffuse Large B Cell Lymphoma
Royal Marsden NHS Foundation Trust
Phase 2 Terminated
NCT00448019 2015-11-02
FCR and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00845104 2015-03-06
Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded To Treatment
Fred Hutchinson Cancer Center
Phase 2 Withdrawn
NCT00193492 2015-01-05
A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00754650 2014-06-26
A Proof of Concept Study of the Safety, Tolerability, and Efficacy of Avastin (Bevacizumab) in Patients With Chemo-naive Chronic Lymphocytic Leukemia
Hoffmann-La Roche
Phase 2 Completed
NCT00121199 2014-05-21
Combination Chemo, Rituximab, and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00290810 2014-05-09
Bevacizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT01921790 2013-08-22
Avastin+ GemAOD As First-Line Treatment in NK/T Cell Lymphoma
Sun Yat-sen University
Phase 2 Unknown
NCT00217503 2013-06-20
Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00016094 2013-01-29
S0108 Bevacizumab in Treating Patients With Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00081861 2012-04-05
Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed